Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab-based CCRT vs CCRT + Durvalumab in Unresectable Stage III NSCLC
2022-502886-71-00Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2023
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Nivolumab + CCRT → Nivolumab + Ipilimumab, Nivolumab + CCRT → Nivolumab and CCRT → Durvalumab (3 arms). Started Apr 2023; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-502886-71-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502886-71-00.